SCHEMBL1447243

SCHEMBL1447243

Cc1cc(Br)ccc1C(=O)N1CCN(C)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.57
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 2/20 0.54
HRH4 Q9H3N8 2/20 0.53
HRH3 Q9Y5N1 1/20 0.53
TSHR P16473 2/20 0.50
ALOX15 P16050 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TP53 P04637 2/20 0.50
DUSP3 P51452 1/20 0.50
PTPN5 P54829 1/20 0.50
PTPN11 Q06124 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 2/20 0.47
HSP90AA1 P07900 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447805 0.94 POLB (0.68) POLBNPC1RAB9ALMNAHRH4
SCHEMBL19086436 0.88 HTT (0.47) POLBNPC1RAB9ALMNAHRH4
SCHEMBL4243617 0.87 HTT (0.58) POLBNPC1RAB9ATSHRALDH1A1
SCHEMBL256310 0.87 HPGD (0.59) POLBNPC1RAB9ALMNATSHR
SCHEMBL2104229 0.86 HPGD (0.59) NPC1RAB9ALMNATSHRALDH1A1
SCHEMBL16129353 0.85 HPGD (0.42) POLBNPC1RAB9AHRH4HRH3
SCHEMBL11961209 0.84 HRH4 (0.54) POLBLMNAHRH4TSHRALOX15
SCHEMBL3732153 0.84 DUSP3 (0.54) HRH4ALDH1A1TP53DUSP3PTPN5
SCHEMBL970089 0.83 HPGD (0.55) POLBRAB9AKMT2AHTTHPGD
SCHEMBL1448439 0.83 LMNA (0.60) POLBNPC1RAB9ALMNAHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3321268-B1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2025-06-04 EP disclosed
EP-3265453-B1 NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 BOEHRINGER INGELHEIM INT (DE) 2022-06-29 EP disclosed
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-03 US disclosed
US-11040978-B2 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-06-22 US disclosed
US-20190315755-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY SCIENCE TECH & RES (SG) 2019-10-17 US disclosed
US-20190211020-A1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-07-11 US disclosed
US-10280168-B2 Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-05-07 US disclosed
US-20180208600-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-07-26 US disclosed
EP-3321268-A1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF Agency For Science, Technology And Research (SG) 2018-05-16 EP disclosed
US-9908886-B2 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-03-06 US disclosed
US-20090054409-A1 IMIDAZO [1,2-A] PYRIDINE HAVING ANTI-CELL-PROLIFERATION ACTIVITY ASTRAZENECA AB (SE) 2009-02-26 US disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 WO disclosed
WO-2008148867-A2 QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES NOVARTIS AG (CH) 2008-12-11 WO disclosed
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders ASTRAZENECA AB (SE) 2008-11-13 US disclosed
CN-101277956-A Imidazo [1,2-A] pyridine having anti-cell-proliferation activity ASTRAZENECA AB (SE) 2008-10-01 CN disclosed
CN-101273031-A Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders ASTRAZENECA AB (SE) 2008-09-24 CN disclosed
EP-1912974-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2008-04-23 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed
WO-2007015064-A1 IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10280168-B2 Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof MAPKAPK2, NEK2, MKNK2 POLB 1006/4885NPC1 2469/4885RAB9A 1936/4885
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 POLB 1721/4885NPC1 1393/4885RAB9A 1528/4885
US-20190315755-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF MAPKAPK2, MKNK2, MAP4K2 POLB 880/4885NPC1 2736/4885RAB9A 3015/4885
US-20090054409-A1 IMIDAZO [1,2-A] PYRIDINE HAVING ANTI-CELL-PROLIFERATION ACTIVITY MKI67, CCNI, CCNA1 POLB 250/4885NPC1 3850/4885RAB9A 2272/4885
US-20080280906-A1 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders CCNI, MKI67, TYMP POLB 50/4885NPC1 1784/4885RAB9A 2667/4885
US-11319318-B2 Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 BRD9, BRD1, BRD2 POLB 958/4885NPC1 4315/4885RAB9A 339/4885
US-20190211020-A1 BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF MAPKAPK2, NEK2, MKNK2 POLB 995/4885NPC1 2480/4885RAB9A 1906/4885
US-20180208600-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF MAPKAPK2, MKNK2, MAP4K2 POLB 880/4885NPC1 2736/4885RAB9A 3015/4885
US-11040978-B2 Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof MKNK2, MKNK1, MAPKAPK2 POLB 585/4885NPC1 1875/4885RAB9A 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.